Molecular Partners AG (XSWX:MOLN)
CHF 3.35 -0.04 (-1.18%) Market Cap: 110.11 Mil Enterprise Value: -60.67 Mil PE Ratio: 0 PB Ratio: 0.65 GF Score: 52/100

Molecular Partners AG at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 03:30PM GMT
Release Date Price: CHF6.04 (-4.13%)
Richard Vosser
JPMorgan Chase & Co, Research Division - Senior Analyst

Welcome to the Molecular Partners Presentation at the 41st JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan, and it's my great pleasure to introduce Patrick Amstutz, the CEO of Molecular Partners. Before I hand over to Patrick, I'd just remind everyone that we will stay in this room for Q&A. And if you just put up your hand and wait for a microphone, and then we'll address your question. Patrick, great to see you.

Patrick Amstutz
Molecular Partners AG - Co-Founder, CEO, Member of Management Board & Director

Thanks, Richard, for the kind intro. My name is Patrick Amstutz, I'm the CEO of Molecular Partners, and a warm welcome to -- from my side to those in the room and also those on the webcast. It's really great to be here and a special thanks to JPMorgan for organizing and making this an in-person meeting. It's been great to be on the street, meet people and truly energizing an important moment, I think, for the industry. So special

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot